What is the recommended asthma management protocol for an adult patient in Australia for a GP, including diagnosis confirmation, initial low‑dose inhaled corticosteroid (ICS) therapy, step‑up to a combination inhaler with long‑acting β2‑agonist (LABA), a personalized asthma action plan, and treatment of acute exacerbations?

Asthma Management in Australia as a GP Doctor

For adult asthma management in Australia, initiate low-dose inhaled corticosteroid (ICS) therapy for all patients with persistent asthma, and for mild asthma specifically, consider as-needed budesonide-formoterol as the preferred reliever therapy rather than salbutamol alone, as this approach reduces severe exacerbations while providing symptom relief. 1

Diagnosis Confirmation

Before initiating treatment, confirm asthma diagnosis through:

• Spirometry with bronchodilator reversibility testing (≥12% and ≥200mL FEV1 improvement)
• Peak expiratory flow monitoring with diurnal variability assessment
• Document symptom patterns: frequency, nocturnal symptoms, exercise limitation
• Assess trigger exposures and atopic history

Critical pitfall: Many Australian adults remain undiagnosed or undertreated—recent data shows 38.1% have uncontrolled symptoms with inadequate ICS use 2.

Initial Therapy: The Stepwise Approach

Step 1-2: Mild Intermittent to Mild Persistent Asthma

Preferred approach (based on updated Australian guidelines):

• As-needed low-dose budesonide-formoterol (160/4.5 μg) as both reliever and anti-inflammatory therapy 1
• This replaces the outdated approach of SABA-only reliever therapy
• Take 1 inhalation whenever symptoms occur, up to maximum 8 inhalations/day for mild asthma

Alternative (if budesonide-formoterol unavailable):

• Daily low-dose ICS (e.g., budesonide 200-400 μg/day or equivalent) PLUS as-needed SABA 3
• Leukotriene receptor antagonist (montelukast 10mg daily) as second-line alternative 3

Rationale: The shift away from SABA monotherapy addresses the concerning finding that 56.3% of Australian adults obtained ≥3 SABA inhalers yearly, with 10.5% obtaining ≥12 inhalers—a pattern associated with increased exacerbation risk 2.

Step 3: Moderate Persistent Asthma

Preferred treatment:

• Low-to-medium dose ICS-LABA combination (e.g., budesonide-formoterol 200/6 μg twice daily) 4, 3
• Use budesonide-formoterol as both maintenance (1-2 inhalations twice daily) AND reliever (additional inhalations as needed, up to 12 total/day) 5

This SMART/MART regimen (Single Maintenance and Reliever Therapy) provides superior exacerbation reduction compared to fixed-dose ICS-LABA plus SABA 6, 5.

Alternative options:

• Medium-dose ICS alone (if LABA contraindicated)
• Low-dose ICS plus leukotriene receptor antagonist 3

Key evidence: Adding LABA to low-dose ICS is more effective than doubling ICS dose for symptom control and lung function 4, 7.

Step 4: Severe Persistent Asthma

Preferred treatment:

• Medium-to-high dose ICS-LABA (e.g., budesonide-formoterol 400/12 μg twice daily) 3
• Continue SMART regimen: 2 inhalations twice daily maintenance, plus as-needed doses (maximum 12 inhalations/day total) 5

If inadequate control:

• Add long-acting muscarinic antagonist (LAMA) such as tiotropium 8
• Consider specialist referral for phenotypic assessment and potential biologics (omalizumab for allergic asthma, anti-IL5/IL4R agents) 9

Step 5-6: Very Severe Asthma

• High-dose ICS-LABA plus oral corticosteroids (prednisolone 30-60mg daily) 4, 3
• Mandatory specialist referral for biologic therapy consideration before committing to long-term oral steroids 9

Personalized Asthma Action Plan

Every patient must receive a written action plan that includes 10:

Green Zone (well-controlled):

• Peak flow >80% personal best
• Continue maintenance therapy
• Use reliever as needed (but <2 days/week indicates poor control)

Yellow Zone (worsening):

• Peak flow 60-80% personal best OR increased symptoms
• Action: Double ICS dose OR increase budesonide-formoterol to 2 inhalations 4 times daily
• If no improvement in 48 hours, start oral prednisolone 30-50mg daily

Red Zone (severe):

• Peak flow <60% personal best OR severe breathlessness at rest
• Action: Take 4-8 puffs SABA via spacer OR 1-2 puffs budesonide-formoterol
• Start prednisolone 30-50mg immediately
• Call ambulance or present to ED

Critical implementation point: Only 42% of Australian ICS users had inhaler technique checked in the past year 2—technique must be verified at every visit.

Acute Exacerbation Management

In general practice setting:

1. Immediate treatment:

   • Oxygen to maintain SpO2 ≥92%
   • SABA 4-8 puffs via spacer every 20 minutes for first hour OR nebulized salbutamol 5mg 10
   • Prednisolone 30-50mg orally (or IV hydrocortisone 100mg if unable to swallow) 10
   • Consider ipratropium bromide 500mcg nebulized if severe 9

2. Assess severity:

   • Life-threatening features: Silent chest, cyanosis, exhaustion, confusion, SpO2 <92%, inability to complete sentences
   • Severe: Peak flow <50% predicted, respiratory rate >25, pulse >110
   • Moderate: Peak flow 50-75% predicted, able to speak in phrases

3. Disposition:

   • Life-threatening or severe with poor response to initial treatment: Immediate hospital transfer 10
   • Moderate with good response: Continue SABA every 3-4 hours, prednisolone 30-50mg daily for 5-7 days, review within 24-48 hours
   • Ensure discharge on higher ICS dose than pre-exacerbation 10

What NOT to do 10:

• No antibiotics unless bacterial infection confirmed
• No sedation (absolutely contraindicated)
• No chest physiotherapy

Essential Follow-Up and Monitoring

At every visit:

• Check and document inhaler technique (use teach-back method)
• Review adherence barriers
• Assess control using validated tool (Asthma Control Test)
• Measure peak flow and compare to personal best
• Review action plan understanding

Post-exacerbation:

• GP review within 1 week of hospital discharge 10
• Respiratory physician follow-up within 1 month 10
• Investigate precipitating factors: allergen exposure, medication non-adherence, viral infection

Step-down considerations:

• Only after ≥3 months of good control 3
• Reduce ICS dose by 25-50% every 3 months
• Never step down during viral season or after recent exacerbation

Common Pitfalls to Avoid

1. SABA overuse: Prescribing >3 SABA inhalers yearly indicates poor control—this pattern affects 56.3% of Australian adults and predicts exacerbations 2

2. Inadequate ICS therapy: 38.1% of Australian adults have uncontrolled symptoms with little/no ICS use, yet 63.5% of this group required urgent healthcare 2

3. Failure to implement anti-inflammatory reliever therapy: Only 13.3% of Australian adults use ICS-formoterol as reliever despite guideline recommendations 2

4. Not checking inhaler technique: This fundamental step is missed in 58% of patients 2

5. Premature step-down: Stepping down before 3 months of stability increases exacerbation risk 3

Australian-Specific Considerations

The 2025 Australian asthma guidelines emphasize:

• Budesonide-formoterol as preferred reliever across all severity levels for adults and adolescents 1
• This represents a fundamental shift from SABA-based reliever therapy
• The approach addresses the concerning worsening of asthma outcomes in Australia between 2012-2021, including decreased symptom control (48% vs 54.4% well-controlled) and increased urgent healthcare use (37.9% vs 28.6%) 2

Practical prescribing: Budesonide-formoterol 200/6 μg (Symbicort Rapihaler or equivalent) is the most studied formulation for SMART regimens in Australia 5, 1.